stiripentol (diacomit) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

  • Now
Stiripentol is an anticonvulsant drug used in the treatment of epilepsy. It recently proved to increase the GABAergic transmission in vitro in an experimental model of immature rat. Clinical studies were based on the fact that STP also acts as an inhibitor of CYP3A4, CYP1A2, and CYP2C19 in vivo in epileptic patients. Side effects are largely due to the increase in plasma concentrations of other anticonvulsants and can be reduced by lowering the dose of those drugs. Nausea and vomiting are particularly noted when used in combination with sodium valproate. It appears to increase the potency of phenobarbital, primidone, phenytoin, carbamazepine, clobazam and diazepam.   NCATS

  • Mol. Mass: 234.2909
  • ALogP: 2.84
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)


$4.0707 - $7.9219

United States

$19.0955 - $38.1910
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1-(1,3-benzodioxol-5-yl)-4,4- dimethyl-1-penten-3-ol | 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol | 4,4-dimethyl-1-((3,4-methylenedioxy)phenyl)-1-penten-3-ol | bcx 2600 | bcx-2600 | brn 1313047 | d-306 | diacomit | estiripentol | stiripentol | stiripentolum


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue